Basilea Pharmaceutica AG (SIX: BSLN.SW) Stock Competitors & Peer Comparison
See BSLN.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BSLN.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BSLN.SW | CHF 69.00 | +0.00% | 854M | 32.69 | CHF 2.11 | N/A |
| LONN.SW | CHF 545.60 | +0.11% | 38.1B | 34.25 | CHF 15.93 | +0.92% |
| BANB.SW | CHF 78.55 | +0.77% | 5.9B | 39.51 | CHF 1.99 | +1.15% |
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| IDIA.SW | CHF 4.84 | -1.22% | 1.3B | -5.59 | -CHF 0.87 | N/A |
| KURN.SW | CHF 16.46 | -4.91% | 649.2M | 90.94 | CHF 0.18 | N/A |
| SANN.SW | CHF 15.94 | +1.27% | 236.4M | -4.16 | -CHF 3.83 | N/A |
| NWRN.SW | CHF 11.14 | +2.58% | 231.8M | -18.03 | -CHF 0.62 | N/A |
| MOLN.SW | CHF 3.46 | +6.46% | 129.8M | -2.55 | -CHF 1.36 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
BSLN.SW vs LONN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, LONN.SW has a market cap of 38.1B. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while LONN.SW trades at CHF 545.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas LONN.SW's P/E ratio is 34.25. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, BSLN.SW is less volatile compared to LONN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
BSLN.SW vs BANB.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, BANB.SW has a market cap of 5.9B. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while BANB.SW trades at CHF 78.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas BANB.SW's P/E ratio is 39.51. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, BSLN.SW is less volatile compared to BANB.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check BANB.SW's competition here
MorphoSys AG (SIX: MOR.SW)
BSLN.SW vs MOR.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, MOR.SW has a market cap of 2.4B. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while MOR.SW trades at CHF 102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas MOR.SW's P/E ratio is -4.03. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MOR.SW's ROE of -1.84%. Regarding short-term risk, BSLN.SW is not fully comparable compared to MOR.SW. This indicates unavailable risk data in terms of short-term price fluctuations for BSLN.SW.Check MOR.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
BSLN.SW vs IDIA.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, IDIA.SW has a market cap of 1.3B. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while IDIA.SW trades at CHF 4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas IDIA.SW's P/E ratio is -5.59. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, BSLN.SW is less volatile compared to IDIA.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check IDIA.SW's competition here
Kuros Biosciences AG (SIX: KURN.SW)
BSLN.SW vs KURN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, KURN.SW has a market cap of 649.2M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while KURN.SW trades at CHF 16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas KURN.SW's P/E ratio is 90.94. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to KURN.SW's ROE of +0.10%. Regarding short-term risk, BSLN.SW is less volatile compared to KURN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check KURN.SW's competition here
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW)
BSLN.SW vs SANN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, SANN.SW has a market cap of 236.4M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while SANN.SW trades at CHF 15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas SANN.SW's P/E ratio is -4.16. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SANN.SW's ROE of +6.85%. Regarding short-term risk, BSLN.SW is less volatile compared to SANN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SANN.SW's competition here
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW)
BSLN.SW vs NWRN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, NWRN.SW has a market cap of 231.8M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while NWRN.SW trades at CHF 11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas NWRN.SW's P/E ratio is -18.03. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to NWRN.SW's ROE of +2.78%. Regarding short-term risk, BSLN.SW is less volatile compared to NWRN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check NWRN.SW's competition here
Molecular Partners AG (SIX: MOLN.SW)
BSLN.SW vs MOLN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, MOLN.SW has a market cap of 129.8M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while MOLN.SW trades at CHF 3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas MOLN.SW's P/E ratio is -2.55. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MOLN.SW's ROE of -0.68%. Regarding short-term risk, BSLN.SW is less volatile compared to MOLN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check MOLN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
BSLN.SW vs RLF.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, BSLN.SW is less volatile compared to RLF.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
BSLN.SW vs MMTX.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, MMTX.SW has a market cap of 23.4M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while MMTX.SW trades at CHF 0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas MMTX.SW's P/E ratio is -0.31. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, BSLN.SW is less volatile compared to MMTX.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check MMTX.SW's competition here
Spexis AG (SIX: SPEX.SW)
BSLN.SW vs SPEX.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, BSLN.SW is less volatile compared to SPEX.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SPEX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
BSLN.SW vs ADXN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, ADXN.SW has a market cap of 3.4M. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while ADXN.SW trades at CHF 0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas ADXN.SW's P/E ratio is -0.39. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to ADXN.SW's ROE of -1.31%. Regarding short-term risk, BSLN.SW is less volatile compared to ADXN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check ADXN.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
BSLN.SW vs OBSN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, BSLN.SW is less volatile compared to OBSN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check OBSN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
BSLN.SW vs SKIN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, BSLN.SW is less volatile compared to SKIN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check SKIN.SW's competition here
Polyphor AG (SIX: POLN.SW)
BSLN.SW vs POLN.SW Comparison September 2026
Basilea Pharmaceutica AG (SIX: BSLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BSLN.SW stands at 854M. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, BSLN.SW is priced at CHF 69.00 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BSLN.SW currently has a P/E ratio of 32.69, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, BSLN.SW's ROE is +0.36%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, BSLN.SW is less volatile compared to POLN.SW. This indicates lower risk in terms of short-term price fluctuations for BSLN.SW.Check POLN.SW's competition here